Please login to the form below

Not currently logged in
Email:
Password:

Axentis Pharma takes over cystic fibrosis patents

Swiss biotech company Axentis Pharma has taken over Austrian-based BioDevelops Pharma, acquiring the rights to key cystic fibrosis screening patents.
Swiss biotech company Axentis Pharma has taken over Austrian-based BioDevelops Pharma, acquiring the rights to key cystic fibrosis screening patents.

Three years ago, the Austrian company identified a new approach to treating cystic fibrosis; targeting the process through which the body destroys its own proteins - the direct cause of cystic fibrosis. The patents also cover the second medical use of Velcade in cystic fibrosis.

Joerg Zielasek, president of Axentis Pharma said: "By acquiring the rights to BioDevelops' technology platform, Axentis Pharma is both enhancing its development pipeline and offering patients and investors extensive prospects for the treatment of this disease."

Cystic fibrosis is a hereditary disease caused by a mutation in the CFTR gene found on chromosome 7. The mutation causes increased secretion deposits on mucous membranes. These deposits lead to lung complications that in turn result in high mortality rates among sufferers.

26th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Measures for measures
Why pharma’s marketing metrics must close the loop...
Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...

Infographics